Transcend Medical, Inc.
Transcend Medical, Inc.™ is focused on the research and development of novel devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. Over two million people in the U.S. alone are afflicted with the disease today and the numbers are expected to grow to three million by the year 2020. The Transcend Medical approach is focused on replacing the current therapies for the treatment of glaucoma with a less invasive procedure and minimal complications.


ForSight Newco II (ForSight VISION2) is developing a proprietary ocular punctal plug drug delivery system. Punctal plugs are a non-invasive drug delivery system capable of delivering a variety of drugs to the eye over time through controlled release to the tear film. Sustained release punctal plugs could potentially replace eye drops for glaucoma, dry eye, allergies and postoperative care, which represent a $6 billion market. In addition, plugs may provide a more effective, convenient and reliable treatment alternative that could ultimately improve patient compliance with their medication and outcomes for their disease.

ForSight Newco II was acquired by and became
a wholly-owned subsidiary of QLT, Inc. in October
of 2007.

QLT Acquires Leading Edge Ocular Drug Delivery System from ForSight Labs


Nexis Vision, Inc.
Nexis Vision is developing next-generation ocular surface technology. The first application targets the global corneal refractive surgery market.


ForSight VISION4, Inc. is focused on developing novel drug delivery therapies for treatment of retinal diseases.


ForSight VISION5, Inc. is evaluating a variety of technologies to address important unmet patient needs in key ophthalmic markets.